Pharmacokinetics of XXXX in normal subjects and @entity1378 @entity1 .

@entity1 @entity8034 @entity3937 @entity1378 @entity3936
Serum and urinary concentrations of @entity3937 ( @entity3936 ) were measured by high-performance liquid chromatography (HPLC) with an electrochemical detector (ECD) in 10 normal subjects and 43 @entity1378 @entity1 after intravenous and oral administration of the drug. The pharmacokinetic parameters of @entity3936 were estimated in 5 normal subjects and 15 @entity1378 @entity1 according to a two-compartment model after intravenous injection of a 10 mg dose. The mean half-life of the distribution phase ( @entity8034 ) was 2.7 +/- 1.0 h (mean +/- SD) and 3.1 +/- 1.4 h and that of the slower-phase ( @entity8034 ) was 20.7 +/- 9.6 h and 18.5 +/- 12.9 h in normal subjects and @entity1378 @entity1 , respectively. There were no significant differences between pharmacokinetic parameters of normal subjects and those of @entity1378 @entity1 . No correlations between free T4 index (FT4I) and pharmacokinetic parameters were observed. Maximum serum @entity3936 concentrations (Cmax) (213 +/- 84 and 299 +/- 92 ng/ml) were attained 1.8 +/- 1.4 h and 2.3 +/- 0.8 h after a single dose of 10 mg in 5 normal subjects and in 15 @entity1378 @entity1 , respectively. In @entity1378 @entity1 the time taken to reach the peak concentration (Tmax) after a single dose of 10 mg was similar to that after a single 15 mg and 30 mg dose. The pharmacokinetic parameters, except Cmax and the area under the curve (AUC), were not affected by the administered dose and those, except Cmax, were not affected by the thyroid function. All urine was collected at intervals of 3 h for the first 12 h and then at 24 h and 48 h after intravenous and oral administration of @entity3936 . In all subjects, @entity3936 rapidly appeared in the urine and the rate of excretion was highest in the first 3 h. The cumulative urinary excretion of @entity3936 was 5.5-8.5% of administered doses in normal subjects and @entity1378 @entity1 . These findings in the present study are compatible with the assumption that the extent of absorption of @entity3936 is high, if not complete, and @entity1378 does not affect the kinetics of @entity3936 , and that interindividual variation is observed in the time taken to reach the peak concentration after oral administration.
